Abstract: The present invention encompasses a phototrophic microorganism with altered and controlled adhesive properties. One aspect of the present invention encompasses a genetically modified phototrophic microorganism capable of controlled adhesion. The microorganism comprises a recombinant nucleic acid construct, wherein the nucleic acid construct comprises an inducible promoter operably-linked to a nucleic acid encoding an adhesion protein.

Abstract: The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce a cellular immune response.

Abstract: The present invention relates to inducing acid resistance in a bacterium and methods of increasing the acid resistance of an acid sensitive bacterium.

Abstract: The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen.

Abstract: A recombinant bacterium capable of reducing tumor growth is provided, wherein said recombinant bacterium is capable of: a. increased expression of a nucleic acid encoding a chemoreceptor that directs chemotaxis towards tumors, b. accumulation in a quiescent tumor, c. hyper-invasion of a tumor, d. reduced fitness in normal tissue, e. enhanced stimulation of the host innate immune responses, f. delivering a tumor specific DNA vaccine vector to a tumor cell, and g. increased bacterium-induced host programmed cell death.

Abstract: A cyanobactenum that produces neutral lipids or alkanes, such as FAME OR FAEE, which may be used for biofuel production.

Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.

Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Abstract: The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen.

Abstract: The present invention encompasses a bacterium that produces fatty acids.

Abstract: The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.

Abstract: A live attenuated derivative of a pathogenic bacterium intended for use as a vaccine.

Abstract: The invention encompasses a recombinant bacterium capable of eliciting an immune response against Streptococcus pneumoniae, a vaccine comprising the bacterium, and methods of using the bacterium.

Abstract: The present invention encompasses a recombinant Yersinia pestis bacterium and a vaccine comprising a recombinant Yersinia pestis bacterium.

Abstract: The present invention encompasses recombinant bacteria and immunogenic compositions comprising the bacteria. The immunogenic composition may be used to induce an immune response against C. perfringens.

Abstract: The invention encompasses compositions and methods for degrading the peptidoglycan layer of a cell wall. In particular, the invention encompasses compositions and methods for degrading the peptidoglycan layer of the cell wall of a gram-negative bacterium.

Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.

Abstract: Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes only in the permissive environment, or expressing one or more lethal genes only in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of required genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into a permissive environment. Temperature regulated Environmentally Limited Viability Systems are particularly suited for use with recombinant avirulent Salmonella vaccines by limiting their growth to the warmer environment inside the host.

Abstract: The invention encompasses a recombinant bacterium that comprises at least one vector capable of expressing a nucleic acid sequence encoding an antigen. In particular, the bacterium comprises at least one chromosomally encoded essential nucleic acid that is altered so that it is not expressed, and at least one extrachromosomal vector.